Acetyl-coenzyme A carboxylases: versatile targets for drug discovery
Open accessAbstract
Acetyl‐coenzyme A carboxylases (ACCs) have crucial roles in fatty acid metabolism in humans and most other living organisms. They are attractive targets for drug discovery against a variety of human diseases, including diabetes, obesity, cancer, and microbial infections. In addition, ACCs from grasses are the targets of herbicides that have been in commercial use for more than 20 years. Significant progresses in both basic research and in drug discovery have been made over the past few years in the studies on these enzymes. At the basic research level, the crystal structures of the biotin carboxylase (BC) and the carboxyltransferase (CT) components of ACC have been determined, and the molecular basis for ACC inhibition by small molecules are beginning to be understood. At the drug discovery level, a large number of nanomolar inhibitors of mammalian ACCs have been reported and the extent of their therapeutic potential is being aggressively explored. This review summarizes these new progresses and also offers some prospects in terms of the future directions for the studies on these important enzymes. J. Cell. Biochem. 99: 1476–1488, 2006. © 2006 Wiley‐Liss, Inc.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Acetyl-CoA carboxylase catalyzes the carboxylation of acetyl-CoA to malonyl-CoA.
“This enzyme catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, which is not only a substrate for fatty acid biosynthesis but is also known to suppress b-oxidation (Tong and Harwood, 2006).”
Acetyl-coenzyme A carboxylase-a is the rate-limiting enzyme in fatty acid synthesis.
“In particular, the upregulation of acetyl-coenzyme A carboxylase-a as the rate-limiting enzyme in fatty acid synthesis (Tong and Harwood, 2006) is noteworthy.”
Malonyl-CoA suppresses beta-oxidation.
“This enzyme catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, which is not only a substrate for fatty acid biosynthesis but is also known to suppress b-oxidation (Tong and Harwood, 2006).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 39 · Cited by 207
Research works printed but not linked: 1
- Perry DA, Harwood HJ Jr, Makowski MR, Coletta CJ, Pyrke-Fairchild J, Petras SF, Shelly LD, Zaccaro LM, Hargrove DM, Martin KA, Dalvie DK, Soliman VF, Mularski CJ, Wester RT, Eisenbeis SA. 2004. Nipecotic acid derivatives as potent, nonselective acetyl-CoA carboxylase inhibitors: A novel approach for obesity: ''Proceedings of the 228th ACS National Meeting.'' Philadelphia, USA, MEDI. 197p.
- Authors
- Tong, L., & Harwood, H. J.
- Affiliations
- Columbia University (US)
- Pfizer (United States) (US)
- Corresponding author
- Tong, Liang
- ORCID
- Tong, Liang
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2006-09-18
- Volume
- 99
- Issue
- 6
- Pages
- 1476-1488
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- PMC
- PMC3837461
- OpenAlex
- W2170647741
- Cited by
- 207
- References
- 39
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 5 · 2022: 9 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 9 · 2017: 10 · 2016: 22 · 2015: 12 · 2014: 17 · 2013: 6 · 2012: 12
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Cellular Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK067238, DK67238)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- acetyl-CoA carboxylase, fatty acid metabolism, biotin carboxylase, carboxyltransferase, enzyme crystal structure, small molecule inhibition, herbicides, diabetes mellitus, obesity, cancer, microbial infection, therapeutic target
- MeSH terms
- Acetyl-CoA Carboxylase, Animals, Enzyme Inhibitors, Humans, Models, Molecular, Protein Conformation, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review